Holen Sie sich die Stockscreener-App
20.18
1.66%
-0.34
Vorhandelsmarkt:
20.76
0.58
+2.87%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Pharmaceutical Inc. $RARE Shares Acquired by Aberdeen Group plc - MarketBeat
CLASS ACTION ALERTS: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
RARE: Evercore ISI Lowers Price Target for Ultragenyx, Maintains Outperform Rating | RARE Stock News - GuruFocus
INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. Investors - GlobeNewswire
Ultragenyx Pharmaceutical (RARE) Analyst Rating: Wedbush Reitera - GuruFocus
Ultragenyx Pharmaceutical's (RARE) Neutral Rating Reaffirmed at Wedbush - MarketBeat
Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: A 190% Potential Upside Awaits Investors - DirectorsTalk Interviews
HC Wainwright Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $50.00 - MarketBeat
RARE: HC Wainwright Lowers Price Target to $50, Maintains Buy Rating | RARE Stock News - GuruFocus
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - PR Newswire
Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) - Yahoo Finance
RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - TMX Newsfile
Ultragenyx cuts 10% of workforce as it targets 2027 profitability - The Pharma Letter
Ultragenyx Plans Workforce Reduction Following FDA Rejection of Gene Therapy Treatment - geneonline.com
Ultragenyx Shareholders Must Apply for Class Action Lawsuit Participation by April 6, 2026 - geneonline.com
Movement Recap: Is Ultragenyx Pharmaceutical Inc stock good for income investorsGlobal Markets & Stepwise Trade Signal Implementation - baoquankhu1.vn
Biggest stock movers Monday: DigitalBridge, Ultragenyx Pharmaceutical - MSN
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - marketscreener.com
Understanding the Setup: (RARE) and Scalable Risk - Stock Traders Daily
Ultragenyx Gene Therapy Progress And Restructuring Meet Deeply Discounted Valuation - Yahoo Finance
Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) ... - Bluefield Daily Telegraph
RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Q4 2025 earnings call transcript - MSN
What’s the outlook for Ultragenyx Pharmaceutical Inc.’s sector2025 Winners & Losers & Low Risk High Reward Ideas - mfd.ru
How Ultragenyx Pharmaceutical Inc. stock reacts to Fed rate cuts2025 Stock Rankings & Smart Allocation Stock Tips - mfd.ru
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2025 Earnings Call Transcript - Insider Monkey
Ultragenyx Pharmaceutical (RARE) TTM US$575 Million Loss Tests Bullish Profitability Narratives - Sahm
Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A - Insider Monkey
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to - pharmiweb.com
Biopharma bites: Layoffs at Ultragenyx, Gilead's licensing deal, plus a pair of PIPEs and a 340B update - FirstWord Pharma
Ultragenyx Pharmaceutical Class Action Update - Intellectia AI
Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action LawsuitContact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - ChartMill
Ultragenyx (RARE) Faces Revenue Shortfall and Workforce Reductio - GuruFocus
Ultragenyx Earnings Call Balances Growth With Risk - TipRanks
Ultragenyx Q4 loss wider than expected, revenues increase Y/Y - MSN
Ultragenyx falls as guidance trails consensus amid job cuts - Seeking Alpha
Ultragenyx cuts jobs as it seeks path to profit in 2027 - BioPharma Dive
Why Is Ultragenyx Stock Sinking Friday?Ultragenyx Pharmaceutical (NASDAQ:RARE) - Benzinga
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Asianet Newsable
Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - Finviz
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Gap Down on Disappointing Earnings - MarketBeat
Ultragenyx to cut 130 jobs following failed rare-disease drug trialSan Francisco Business Times - The Business Journals
Ultragenyx Pharmaceutical Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Truist Cuts Price Target on Ultragenyx Pharmaceutical to $76 From $90, Keeps Buy Rating - marketscreener.com
Ultragenyx Pharmaceutical Q4 2025 Earnings Call Transcript - MarketBeat
Ultragenyx (RARE) Q4 2025 Earnings Call Transcript - The Globe and Mail
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans - Fierce Biotech
Layoff Tracker: Ultragenyx Downsizes By 10% After Bone Drug’s Phase 3 Fail - BioSpace
Investors in Ultragenyx Pharmaceutical Inc. Should Contact The Gross Law Firm Before April 6, 2026 to Discuss Your RightsRARE - The Malaysian Reserve
ROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - TMX Newsfile
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx - GlobeNewswire
ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Ultragenyx Pharmaceutical Q4 Earnings Call Highlights - MarketBeat
4.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):